Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
79.30B
Market cap79.30B
Price-Earnings ratio
18.76
Price-Earnings ratio18.76
Dividend yield
0.48%
Dividend yield0.48%
Average volume
922.37K
Average volume922.37K
High today
$782.59
High today$782.59
Low today
$763.31
Low today$763.31
Open price
$767.98
Open price$767.98
Volume
507.15K
Volume507.15K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

With a market cap of 79.3B, Regeneron(REGN) trades at $768.58. The stock has a price-to-earnings ratio of 18.76 and currently yields dividends of 0.48%.

As of 2026-08-06, Regeneron(REGN) stock has fluctuated between $763.31 and $782.59. The current price stands at $768.58, placing the stock +0.7% above today's low and -1.8% off the high.

Regeneron(REGN) shares are trading with a volume of 507.15K, against a daily average of 922.37K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

REGN News

TipRanks 17h
Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

Simply Wall St 2d
Does Regeneron Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?

Regeneron Pharmaceuticals, Inc. previously reported second-quarter 2026 revenue of US$4,290.7 million versus US$3,675.6 million a year earlier, while net income...

Does Regeneron Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?
TipRanks 3d
Regeneron price target raised to $1,030 from $1,000 at Guggenheim

Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,030 from $1,000 and keeps a Buy rating on the shares following what the firm calls ” a clean...

Analyst ratings

65%

of 31 ratings
Buy
64.5%
Hold
35.5%
Sell
0%

More REGN News

Simply Wall St 3d
Regeneron Pharmaceuticals Posts Strong Q2 Revenue, Is The Upside Already Priced In?

Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend de...

Regeneron Pharmaceuticals Posts Strong Q2 Revenue, Is The Upside Already Priced In?
TipRanks 6d
Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to...

Nasdaq 6d
Regeneron Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Regeneron Q2 2026 Earnings Call Transcript
TipRanks 6d
Regeneron Earnings Call Highlights Dupixent-Driven Surge

Regeneron Pharmaceuticals ((REGN)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing...

Benzinga 7d
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6% to 5.154 billion euros, above 5 billion euros per quarter for the first t...

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
The Wall Street Journal 7d
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.